التفاصيل البيبلوغرافية
| العنوان: |
Serum levels of P-glycoprotein and persistence of disease activity despite treatment in patients with systemic lupus erythematosus. |
| المؤلفون: |
Perez-Guerrero, Edsaul Emilio, Gamez-Nava, Jorge Ivan, Muñoz-Valle, Jose Francisco, Cardona-Muñoz, Ernesto German, Bonilla-Lara, David, Fajardo-Robledo, Nicte Selene, Nava-Zavala, Arnulfo Hernan, Garcia-Cobian, Teresa Arcelia, Rincón-Sánchez, Ana Rosa, Murillo-Vazquez, Jessica Daniela, Cardona-Müller, David, Vazquez-Villegas, Maria Luisa, Totsuka-Sutto, Sylvia Elena, Gonzalez-Lopez, Laura |
| المصدر: |
Clinical & Experimental Medicine; Feb2018, Vol. 18 Issue 1, p109-117, 9p |
| مصطلحات موضوعية: |
SYSTEMIC lupus erythematosus treatment, P-glycoprotein, THERAPEUTIC use of glucocorticoids, DRUG resistance, BLOOD serum analysis |
| مستخلص: |
Around 25% of patients with systemic lupus erythematosus (SLE) could be refractory to conventional therapies. P-glycoprotein expression on cell surface has been implied on drug resistance, however, to date, it is unknown if P-gp serum levels are associated with SLE disease activity. Evaluate the association of serum P-gp levels and SLE with disease activity despite treatment. A cross-sectional study was conducted on 93 female SLE patients, all receiving glucocorticoids at stable doses for the previous 6 months before to baseline. SLE patients were classified into two groups: (a) patients with active disease [SLE disease activity index (SLEDAI) ≥ 3] despite treatment, and (b) patients with inactive disease (SLEDAI < 3) after treatment. Forty-three healthy females comprised the control group. Serum P-gp, anti-DNA, and both anti-nucleosome antibody levels were measured using ELISA. Active-SLE patients despite treatment had higher P-gp levels compared with inactive-SLE after treatment (78.02 ng/mL ± 114.11 vs. 33.75 ng/mL ± 41.11; p = 0.018) or versus reference group subjects (30.56 ng/mL ± 28.92; p = 0.011). P-gp levels correlated with the scores of SLEDAI (r = 0.26; p = 0.01), Mexican-SLEDAI (MEX-SLEDAI) (r = 0.32; p = 0.002), SLICC/ACR damage index (r = 0.47; p < 0.001), and with prednisone doses (r = 0.33; p = 0.001). In the multivariate model, the high P-gp levels were associated with SLICC/ACR score (p = 0.001), and SLEDAI score (p = 0.014). Our findings support a relationship between serum P-gp levels and SLE with disease activity despite treatment, but it requires further validation in longitudinal studies. [ABSTRACT FROM AUTHOR] |
|
Copyright of Clinical & Experimental Medicine is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |